SANTA CLARA, Calif., Jan. 8, 2014 , PRNewswire -- ProteinSimple today introduced Wes, another revolutionary re-invention of the Western blot. Wes is the bold evolution of the popular Simple Western family of instruments, delivering simplicity and performance like no product before it. With just 30 minutes of sample prep, Wes will analyze up to 25 samples in under 3 hours and he will do it all for less than the price of a high-end Western imager. Wes also introduces an innovative suite of consumables that streamline assay workflow and delivers sensitivity that is better than any traditional Western.
When the Simple Western launched in 2011, it changed the Western blot world forever. It eliminated the hassles of traditional Western blots — no more messy gels, no transfer tanks, no blots, no imaging and no manual analysis. All the steps of the Simple Western are automated, and quantitative data is delivered in a matter of hours.
Wes elevates the Simple Western platform to a stunning level of simplicity. Wes assay kits come with a microplate pre-filled with all the required reagents, fully prepared and ready to use. Researchers only need to pipette their sample and primary antibody into the microplate. Then, simply insert the plate and a disposable capillary cartridge into the instrument. From there, Wes runs the chosen assay and delivers fully analyzed data. The researcher can then dispose of the plate and cartridge and Wes is completely ready for the next experiment.
Read more: http://www.proteinsimple.com/news_details.html?id=48&page=news.html
Soft Tissue Regeneration, Inc. Announces Financing and Appoints New Members to Board of Directors
Sara Ansari, R.D. Registered Dietitian, Nutrition Consultant, and Prevent Health Coach joins Lisa and talks anout the biggest obstacles to healthy eating that people face during the holiday season, best tips and strategies to staying healthy while at a holiday party, things people can do to mentally prepare for the holidays, emotional and stress eating and more!
SAN DIEGO, Dec. 19, 2013 – ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today that Mark G. Foletta has been appointed to its Board of Directors. Mr. Foletta is a seasoned financial executive with over 30 yearsof corporate experience. He was most recently senior vice president and Chief Financial Officer at Amylin Pharmaceuticals, Inc. He joined Amylin in 2000 and served through its acquisition by Bristol-Myers Squibb forapproximately $7 billion in August 2012. During his time at Amylin the company grew from 75 to over 1,300 employees and he was instrumental leading numerous strategic transactions with global pharmaceutical companies, as well as public and private financing transactions. As chair of Amylin’s Operating Committee, he had responsibility for business planning, forecasting and assessing performance. He also participated in the commercial launch of three novel pharmaceutical products that generated annual revenues reaching over $700M. Prior to Amylin, Mr. Foletta worked 14 years at Intermark, Inc./Triton Group Ltd. where he served as senior vice president,Chief Financial Officer and Corporate Secretary.
MALVERN, Pa., Dec. 17, 2013 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the closing of its initial public offering of 7,150,000 shares of its common stock at a public offering price of$7.00 per share, before the underwriting discount and offering costs. As a result, aggregate net proceeds to TetraLogic, after the underwriting discount and offering costs, were approximately $43,100,000.
GUEST MENTOR Andréa Mallard, Chief Brand Officer at Omada Health: As an entrepreneur, the problem with negative feedback of any kind is that it’s instantly personal: they might as well have called your newborn ugly.
OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple Anti-Cancer Stem Cell Therapeutics to Offer Potential Benefits to Cancer Patients
REDWOOD CITY, Calif., Dec. 3, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED) and Celgene Corporation (Nasdaq:CELG) today announced an agreement to jointly develop and commercialize up to six anti-cancer stem cell (CSC) product candidates from OncoMed's biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4).
...One Bay Area–based company, Omada Health, is making strides in addressing the prediabetes epidemic. The Omada Health program, Prevent, is an online version of a 2002 government-financed project sponsored by the National Institutes of Health called the Diabetes Prevention Program, which found that behavioral weight-loss programs can be more effective at combating diabetes than medication.
ViaCyte Granted Over 20 Patents in 2013 Further Establishing the Company as a Leader in the Field of Regenerative Medicine
San Diego, California, October 29, 2013 — ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that the Company was granted over 20 patents worldwide in 2013 thus far, three U.S. and twenty foreign. These patents enhance the Company’s already strong proprietary position for its VC-01™ combination product as well as other applications of its broad technology platform.
AtheroMed announces results of the EASE study evaluating the Phoenix Atherectomy System in treating peripheral artery disease
MENLO PARK, CA – October 21, 2013 – AtheroMed, a developer of innovative catheter technologies for treating peripheral artery disease (PAD), announced results from its Endovascular Atherectomy Safety and Effectiveness (EASE) study during a Late Breaking Clinical Trials Session at the Vascular Interventional Advances (VIVA) 2013 conference in Las Vegas. Stephen Williams, MD, Director of the Vascular Medicine Center at Johns Hopkins University, presented the results of the study, which demonstrate the safety and effectiveness of the Phoenix Atherectomy System in treating PAD.